HOME >> BIOLOGY >> NEWS
Reversal of symptoms in an autism spectrum disorder

uda Zoghbi, M.D., Professor, Departments of Molecular and Human Genetics, Pediatrics, Neurology, and Neuroscience at Baylor College of Medicine discovered that RTT is caused by mutations in the MECP2 gene. Mutations in MECP2 are now being seen in some cases of childhood schizophrenia, classic autism and learning disabilities.

"The findings are extraordinary, and are of relevance not only to Rett Syndrome but to a much broader class of disorders, including autism and schizophrenia. The successful restoration of normal function demonstrated in the mouse models suggests that if we can develop therapies to address the loss of MECP2 we may be able to reverse neurological damage in children and adults with Rett, autism and related neuropsychiatric disorders," commented Zoghbi.

The reversal experiments were carried out in the Bird lab by research assistant Jacky Guy. Employing technology known as Cre-lox recombination, she created mouse models in which MECP2 was silenced by insertion of a Stop cassette into the gene, resulting in the neurological deficits seen in RTT. Silencing could be reversed at will by removing the Stop cassette, thereby reactivating the MECP2 gene. This was achieved by treating the mice with a drug that caused the enzyme Cre to enter the cell nucleus where it could splice out the cassette.

As well as losing overt behavioral defects, the mice also recovered a key electrophysiological function of the brain. This was determined by measuring LTP (long-term potentiation) which provides a quantifiable measurement of the ability of neurons to respond to stimulation. LTP has long been thought to reflect the cellular basis of learning and memory. Though LTP in RTT mice models was defective, it was restored to normal function by the reversal experiments.

"The reversal of neurological defects, reported in the remarkable article by Guy et al, is surprising because the cause of the symptoms occurred early in development
'"/>

Contact: Monica Coenraads
monica@rsrf.org
203-243-5733
Rett Syndrome Research Foundation
8-Feb-2007


Page: 1 2 3

Related biology news :

1. Reversal of role for a viral protein associated with the development of lymphoma
2. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
3. MIT researchers reverse symptoms in mice of leading inherited cause of mental retardation
4. Latest data shows MabThera provides significant, sustained relief from symptoms of RA
5. OSA symptoms more common among African-American women than Caucasians
6. Gene malfunctions cause schizophrenia, depression symptoms in mice
7. Switching genes to overdrive improves muscular dystrophy symptoms in mice
8. Malaria drug may treat metabolic syndromes many symptoms
9. Brain protein improves stroke symptoms in rats, even when injected after 3 days
10. Rush and UCSF found gene therapy appeared to reduce symptoms of Parkinsons by 40 percent
11. Epilepsy drug eases symptoms of inherited disorder that weakens muscles

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... it is exhibiting in booth 513 at the Association of Community Cancer Centers ... Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations ...
(Date:3/29/2017)... and NEWARK, Del. , March ... privately-held regenerative medicine company, and W. L. Gore ... company, today announced a collaborative research agreement whereby the ... cell therapy delivery device technologies that provide protection from ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
(Date:3/29/2017)... 29, 2017 Research and Markets has ... and Global Markets" report to their offering. ... The study ... sequencing, biochips, RNA interference, synthetic biology tools and genome editing ... These technologies and products are analyzed to determine ...
Breaking Biology Technology:
Cached News: